Enfortumab vedotin clinical trials
8 indexed studies · 2 currently recruiting
- Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
For: Urothelial CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is looking at a new combination of treatments for advanced bladder cancer. Doctors want to see how safe and effective a new drug, sacituzumab tirumotecan, is when given with enfortumab vedotin. It's a key step in finding better ways to treat this type of cancer.
For: Metastatic Urothelial Carcinoma · Locally Advanced Urothelial CarcinomaUnited States · Canada · France - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
For: Muscle Invasive Bladder CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
This study looks at new treatments for muscle-invasive bladder cancer — that's bladder cancer that's grown into the muscle layer. It compares surgery alone with surgery plus new drug treatments for people who can't have or choose not to have standard chemotherapy.
For: Urinary Bladder Cancer, Muscle-invasiveUnited States · Argentina · Australia - RecruitingPHASE1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
This study is looking at a new medicine called LOXO-435 for cancers, especially bladder cancer, that have a specific gene change (FGFR3). It checks how safe and effective LOXO-435 is, both alone and with other standard treatments, to see if it can help patients.
For: Urinary Bladder Neoplasms · Neoplasm Metastasis · Ureteral NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
This study explores new ways to treat bladder cancer, specifically a type that has grown into the bladder muscle. Researchers are testing a new treatment, intismeran autogene, with an existing cancer drug, pembrolizumab, to see if it can stop the cancer from coming back after surgery.
For: Bladder CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE2
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
This study is testing a new medicine, enfortumab vedotin, alone or with pembrolizumab, for certain advanced solid cancers. It aims to see how well these treatments shrink tumours and if they are safe.
For: Locally Advanced or Metastatic Malignant Solid TumorsUnited States · Canada · Japan